Hypogonadism in chronic obstructive pulmonary disease: Incidence and effects

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 2, 2012, Pages 112-117

  Balasubramanian, Vijay ^a   Naing, Soe ^b  

^a Neurosciences Critical Care Units   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chronic obstructive pulmonary disease; hypogonadism; testosterone deficiency

Indexed keywords

GLUCOCORTICOID; TESTOSTERONE;

ANDROGEN THERAPY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEPRESSION; DRUG MEGADOSE; HUMAN; HYPOGONADISM; INCIDENCE; MUSCLE MASS; MUSCLE STRENGTH; MUSCLE WEAKNESS; OSTEOPOROSIS; PATIENT SELECTION; PREVALENCE; REVIEW; SYSTEMIC DISEASE;

AGE FACTORS; AGED; ANDROGENS; BODY MASS INDEX; COMORBIDITY; DEPRESSION; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; INCIDENCE; MALE; MIDDLE AGED; MUSCLE WEAKNESS; OSTEOPOROSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TESTOSTERONE;

EID: 84856676238     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32834feb37     Document Type: Review

References (53)

1. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with & androgen deficiency syndromes: an Endocrine Society clinical practice guide line. J Clin Endocrinol Metab 2010; 95:2536-2559.
2. Araujo AB, Dixon JM, Suarez EA, et al. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2011; 96:3007-3019.
3. Petak SM, Nankin HR, Spark RF, et al. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients: 2002 update. Endocr Pract 2002; 8:440-456.
4. Araujo AB, O'Donnell AB, Brambilla DJ, et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89:5920-5926. (Pubitemid 39628393)
5. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86:724-731. (Pubitemid 32207487)
6. Vermeulen A, Kaufman JM. Diagnosis of hypogonadism in the aging male. Aging Male 2002; 5:170-176. (Pubitemid 35370380)
7. Van Vliet M, Spruit MA, Verleden G, et al. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172:1105-1111. (Pubitemid 43066645)
8. Laghi F, Antonescu-Turcu A, Collins E, et al. Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life. Am J Respir Crit Care Med 2005; 171:728-733. (Pubitemid 40471143)
9. Kamischke A, Kemper DE, Castel MA, et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J 1998; 11:41-45. (Pubitemid 28081793)
10. Debigare R, Marquis K, Cote CH, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003; 124:83-89. (Pubitemid 36851335)
11. Kalyani RR, Gavini S, Dobs AS. Male hypogonadism in systemic disease. Endocrinol Metab Clin North Am 2007; 36:333-348. (Pubitemid 46817893)
12. Karagiannis A, Harsoulis F. Gonadal dysfunction in systemic diseases. Eur J Endocrinol 2005; 152:501-513. (Pubitemid 40575794)
13. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2002; 87:589-598. (Pubitemid 34158223)
14. Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008; 93:2737-2745. (Pubitemid 352008544)
15. Kirbas G, Abakay A, Topcu F, et al. Obstructive sleep apnoea, cigarette smoking and serum testosterone levels in a male sleep clinic cohort. J Int Med Res 2007; 35:38-45. (Pubitemid 46477526)
16. Karadag F, Ozcan H, Karul AB, et al. Sex hormone alterations and systemic inflammation in chronic obstructive pulmonary disease. Int J Clin Pract 2009; 63:275-281.
17. Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest 2005; 28:14-22.
18. Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:870-878. (Pubitemid 39346482)
19. Gosney JR. Atrophy of Leydig cells in the testes of men with longstanding chronic bronchitis and emphysema. Thorax 1987; 42:615-619. (Pubitemid 17118733)
20. Semple PD, Beastall GH, Brown TM, et al. Sex hormone suppression and sexual impotence in hypoxic pulmonary fibrosis. Thorax 1984; 39:46-51. (Pubitemid 14154210)
21. Semple PD, Beastall GH, Watson WS, Hume R. Serum testosterone depression associated with hypoxia in respiratory failure. Clin Sci (Lond) 1980; 58:105-106. (Pubitemid 10062141)
22. Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J Suppl 2003; 46:76s-80s. (Pubitemid 37351739)
23. Crawford BA, Liu PY, Kean MT, et al. Randomized placebo-controlled trial of androgen effects on muscle and bone in men requiring long-term systemic glucocorticoid treatment. J Clin Endocrinol Metab 2003; 88:3167-3176. (Pubitemid 36877490)
24. Svartberg J. Androgens and chronic obstructive pulmonary disease. Curr & Opin Endocrinol Diabetes Obes 2010; 17:257-261.
25. Nowinski A, Kaminski D, Korzybski D, et al. COPD patients with hypogonad-ism are more hypoxic and hypercapnic during exacerbation than patients with normal testosterone level. In: Proceedings of the European Respiratory Society Conference; 8 October 2008; London, UK. E4504.
26. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104:648-651. (Pubitemid 16114558)
27. Creutzberg EC, Schols AM. Anabolic steroids. Curr Opin Clin Nutr Metab Care 1999; 2:243-253. (Pubitemid 129627824)
28. Griggs RC, Kingston W, Jozefowicz RF, et al. Effect of testosterone on muscle mass and muscle protein synthesis. J Appl Physiol 1989; 66:498-503. (Pubitemid 19056118)
29. Li J, Al-Azzawi F. Mechanism of androgen receptor action. Maturitas 2009; 63:142-148.
30. Balasubramanian VP, Varkey B. Chronic obstructive pulmonary disease: effects beyond the lungs. Curr Opin Pulm Med 2006; 12:106-112. (Pubitemid 44384784)
31. Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 1987; 8:1-28.
32. American Thoracic Society/European Respiratory Society. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med 1999; 159:S1-S40.
33. Whittom F, Jobin J, Simard PM, et al. Histochemical and morphological characteristics of the vastus lateralis muscle in patients with chronic obstructive pulmonary disease. Med Sci Sports Exerc 1998; 30:1467-1474. (Pubitemid 28465510)
34. Bernard S, LeBlanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 158:629-634. (Pubitemid 28378196)
35. Hamilton AL, Killian KJ, Summers E, Jones NL. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med 1995; 152:2021-2031.
36. Mostert R, Goris A, Weling-Scheepers C, et al. Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med 2000; 94:859-867.
37. Marquis K, Debigare R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 809-813.
38. Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171:972-977. (Pubitemid 40616945)
39. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003; 58:752-756. (Pubitemid 37094049)
40. Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:1414-1418. (Pubitemid 33124019)
41. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996; 156:1173-1177. (Pubitemid 26196245)
42. Svartberg J, Schirmer H, Medbo A, et al. Reduced pulmonary function is associated with lower levels of endogenous total and free testosterone. The Tromso study. Eur J Epidemiol 2007; 22:107-112. (Pubitemid 46457302)
43. Halabi S, Collins EG, Thorevska N, et al. Relationship between depressive symptoms and hypogonadism in men with COPD. COPD 2011; 8:346-353.
44. Compston JE. Sex steroids and bone. Physiol Rev 2001; 81:419-447. (Pubitemid 32096180)
45. Vanderschueren D, Gaytant J, Boonen S, Venken K. Androgens and bone. Curr Opin Endocrinol Diabetes Obes 2008; 15:250-254. (Pubitemid 351595190)
46. Iqbal F, Michaelson J, Thaler L, et al. Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function. Chest 1999; 116:1616-1624. (Pubitemid 30012703)
47. Biskobing DM. COPD and osteoporosis. Chest 2002; 121:609-620. (Pubitemid 34133004)
48. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85:2670-2677. (Pubitemid 32269134)
49. Ferreira IM, Verreschi IT, Nery LE, et al. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 1998; 114:19-28. (Pubitemid 28337356)
50. Schols AM, Soeters PB, Mostert R, et al. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 1995; 152:1268-1274.
51. Svartberg J, Aasebo U, Hjalmarsen A, et al. Testosterone treatment improves body composition and sexual function in men with COPD, in a 6-month randomized controlled trial. Respir Med 2004; 98:906-913. (Pubitemid 39069342)
52. Laghi F, Langbein WE, Antonescu-Turcu A, et al. Respiratory and skeletal muscles in hypogonadal men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171:598-605. (Pubitemid 40365415)
53. Liu PY, Yee B, Wishart SM, et al. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab 2003; 88:3605-3613. (Pubitemid 37034502)